Abbreviations: CNI 5 calcinerin inhibitor; mTOR 5 mammalian target of rapamycin; TNF 5 tumor necrosis factor
common for these drugs to be administered and monitored by primary pulmonologists in community settings.
The objective of this guideline 1 is to provide recommendations for monitoring the use of immunosuppressive drugs so that clinically signifi cant side effects can be either avoided or recognized in a timely fashion. This guideline does not provide recommendations concerning indications for use of these drugs. Rather, it should be used exclusively to achieve maximal patient safety when these nonsteroidal immunosuppressive medications are prescribed. Suffi cient information related solely to treating pulmonary diseases was available for some of the drugs covered by this guideline; however, recommendations were partially or entirely abstracted from nonpulmonary studies for a number of these agents because of a lack of information in the published literature about their use for pulmonary disorders or for lung transplant recipients. Because of its focus on common and unique side effects associated with specifi c drugs, this guideline can provide important information to both physicians and patients. Treating physicians are also encouraged to use other resources (eg, package inserts and regulatory agency guidelines, such as the US Food and Drug Administration MedWatch program, Micromedex, T he use of nonsteroidal immunosuppressive drugs to treat systemic and pulmonary infl ammatory disorders has increased considerably. These drugs are used to prevent and suppress posttransplant lung allograft rejection and to treat various forms of infl am matory lung disease, such as sarcoidosis, pulmonary vasculitis, and idiopathic interstitial pneumonias. Because these medications have become more widely used for a variety of indications, it has become increas ingly that specifi c comments may need to be updated on the basis of new information as it appears in the literature, and new sections will be added as new immunosuppressive agents are approved for clinical use. As chairs and panelists of the Guidelines Committee, we appreciate comments and corrections from the pulmonology community. We thank the American College of Chest Physicians for its help in developing these guidelines, specifi cally Joe Ornelas, Sandra Lewis , the Health and Science Policy Committee, and the American College of Chest Physicians Board of Regents. and Arthri tis Foundation statements and guidelines) to maximize patient safety. These guidelines were developed by a carefully selected committee of pulmonologists and pharmacists with expertise in the use of these drugs for lung transplantation and infl ammatory lung disease. Committee members not only were experts in the fi eld but also used these drugs in their clinical practices. The ultimate goal of the guideline is to provide an easily accessible, single source that is based on the bestavailable evidence in best practices for monitor ing these drugs and preventing adverse events related to therapy .
Summary of Recommendations
Specifi c guidelines for each drug are provided. One section of the document reviews the evidence for potential toxic side effects of each drug as well as protocols for monitoring therapy that are based on clinical reports for pulmonary conditions. Studies for nonpulmonary conditions are included if important cautions and monitoring information did not exist in the pulmonary literature. Therefore, this guideline provides two levels of recommendations. The fi rst level comprises evidence-based recommendations (formal recommendations made on the basis of evidence obtained from a comprehensive literature review) that were reviewed by the committee for quality and graded. The second level comprises a section for each drug that outlines what clinicians should consider when using these drugs to treat patients; these recommendations focus on issues where there was no evidence in the pulmonary literature to support specifi c recommendations. These are based on expert consensus and recommendations from a variety of sources and summarize what is commonly done to monitor patients when treated with a specifi c medication. For example, cyclophosphamide can cause neutropenia; hence, patients should have their WBC counts monitored during treatment. However, no study could be found that specifi cally compared monitoring blood counts monthly vs weekly.
This guideline also contains a general section regarding the use of immunosuppressive drugs, including a review of drug/drug interactions and a summary of recommendations regarding the various antibiotic prophylaxis regimens that should be considered for use when intense immunosuppression is given (eg, as must be done for lung transplant recipients). These prophylactic regimens have markedly reduced certain infections, such as Pneumocystis jiroveci pneumonia and cytomegalovirus infection. The use of a specifi c antibiotic agent for prophylaxis depends on the clinical situation; once the decision has been made to give prophylaxis, this section helps to defi ne what regimen should be considered.
The guideline is a Web-based document. Although we have used currently available information, we realize 
IL-2 Receptor Antagonists

3.4a. For patients who undergo IL-2 receptor antagonist therapy, monitoring for infusion reactions is recommended (Grade 1C) .
3.4b. For patients who undergo IL-2 receptor antagonist therapy, monitoring of renal function, CBC counts, and infection is recommended (Grade 1C
) .
3.4c. For patients who undergo IL-2 receptor
antagonist therapy, the simultaneous use of either basiliximab (Grade 1C) or daclizumab (Grade 1B) with antilymphocyte antibodies is not recommended.
Cytotoxic Agents
3.5a.
For patients who will undergo concurrent therapy with azathioprine and allopurinol, a reduction in dose of azathioprine is recommended (Grade 1A) .
3.5b. For patients who undergo azathioprine therapy, obtaining CBC counts and renal/hepatic profi les every 1 to 3 months is recommended (Grade 1B) .
3.5c. For patients who will undergo cyclophosphamide therapy, monitoring of CBC count, renal profi le, and urinalysis at least monthly for dose adjustment is recommended (Grade 1B) .
3.5d.
For patients who will undergo cyclophosphamide therapy, increased fl uid intake (eg, 2 L in addition to normal intake in adults; additional 3.1h. For patients with a history of congestive heart failure who undergo anti-TNF-a therapy, close observation for congestive heart failure exacerbation is recommended (Grade 1C) .
3.1i. For patients with a history of demyelinating disease, administration of etanercept is not recommended (Grade 1C)
, and administration of adalimumab and infl iximab is not suggested (Grade 2C) . 3.1j. For patients with no history of demyelinating disease who undergo anti-TNF-a therapy and experience symptoms or display signs of a demyelinating process, discontinuation of therapy is suggested (Grade 2C) .
3.1k. For patients who undergo anti-TNF-a
ther apy and develop symptoms of a lupus-like disorder, discontinuation of therapy is suggested (Grade 2C) .
3.1l.
For patients who will undergo anti-TNF-a therapy and who are at risk for viral hepatitis, serologic screening for hepatitis B is recommended prior to treatment (Grade 1C) .
3.1m. For patients who have hepatitis B virus infection, anti-TNF-a therapy should not be administered (Grade 1C
3.1n. For patients who undergo anti-TNF-a therapy and develop unresolved infections, discontinuation of treatment until the infection is resolved is recommended (Grade 1B) .
3.1o. For patients who are pregnant, administration of anti-TNF-a therapy is used only if alternatives are not able to be used (Grade 2C) .
Calcineurin Inhibitors
3.2a.
For patients who will undergo calcineurin inhibitor (CNI) therapy, the monitoring of drug concentrations, BP, glucose, potassium, magnesium, lipids, CBC count, and renal function is recommended (Grade 1B) . 3.2b. For patients who undergo CNI therapy, monitoring of drug levels when CYP3A4 inducers or inhibitors are added or stopped and adjusting doses are recommended when using cyclosporin A (Grade 1A) or tacrolimus (Grade 1B) therapy.
3.2c. For lung transplant recipients receiving CNI therapy who develop renal dysfunction, a reduction in the target dose concentration is suggested (Grade 2C) .
Mammalian Target of Rapamycin (mTOR) Inhibitors
3.6a. For patients who will undergo mTOR inhibitor therapy, obtaining cholesterol and triglyceride levels prior to treatment is recommended (Grade 1B 
